Wealth Enhancement Advisory Services
CRDL

Wealth Enhancement Advisory Services’s Cardiol Therapeutics CRDL Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6K Buy
+22,340
New +$28.3K ﹤0.01% 4024
2026
Q1 		– Sell
-16,552
Closed -$16.6K – 3639
2025
Q4 		$16.6K Sell
16,552
-218
-1% -$228 ﹤0.01% 3596
2025
Q3 		$17.8K Sell
16,770
-70
-0.4% -$85 ﹤0.01% 3516
2025
Q2 		$25.9K Buy
+16,840
New +$19.6K ﹤0.01% 3280
2025
Q1 		– Sell
-13,538
Closed -$17.3K – 3017
2024
Q4 		$17.3K Sell
13,538
-162
-1% -$273 ﹤0.01% 2906
2024
Q3 		$27.1K Buy
+13,700
New +$28.4K ﹤0.01% 2655

Other funds holding CRDL

PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return

Wealth Enhancement Advisory Services's CRDL Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Cardiol Therapeutics (CRDL) in Q2 2026: 22,340 shares worth $22.6K. The stake represents ﹤0.01% of the portfolio and ranks #4024 among its holdings. This is a return to the name: Wealth Enhancement Advisory Services previously reported a position in CRDL as recently as Q4 2025.

Wealth Enhancement Advisory Services first reported a position in CRDL in Q3 2024 and has held it in 6 quarters since. The position peaked at $27.1K in Q3 2024. 3 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Wealth Enhancement Advisory Services held 22,340 shares of Cardiol Therapeutics worth $22.6K as of Q2 2026.
  • Cardiol Therapeutics was a new Wealth Enhancement Advisory Services position in Q2 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #4024 holding.
  • Wealth Enhancement Advisory Services first reported a position in Cardiol Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Cardiol Therapeutics position peaked at $27.1K in Q3 2024.
  • 3 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.